Comparing Demographic Factors and Outcomes of Pregnant Patients Taking and Not Taking Medication for Opioid Use Disorder in Delaware [ID 1457]

INTRODUCTION: Delaware has one of the highest rates of overdose-related deaths in the United States, ranking fourth highest in 2022. In pregnancy, opioid use disorder (OUD) is associated with increased risks of growth restriction, abruption, and preterm birth (PTB). Medication for opioid use disorder (MOUD) has been shown to decrease the rate of PTB and growth restriction. This study compares demographics and fetal outcomes of patients with opioid use on MOUD and not on MOUD. METHODS: This was a retrospective study obtained via chart review, deidentified, and included all women with a positive urine drug screen for opioids who delivered in a Delaware community hospital between January 2018 and December 2021. RESULTS: Four hundred forty-one (65.3%) of patients were on MOUD. Patients on MOUD were statistically more likely to be White ( P <.001), on Medicaid ( P <.001), and have infant admission to neonatal intensive care unit ( P =.009). There was not significant difference in preterm birth ( P =.71), type of preterm birth ( P =.58), delivery type ( P =.09), 5-minute APGAR of less than 7 ( P =.27), maternal length of stay ( P =.09), emergency department utilization ( P =.21), or number of prenatal visits ( P =.11) for patients on MOUD. CONCLUSIONS/IMPLICATIONS: In contrast to available data in the literature, in this study, MOUD did not reduce the rate of PTB, and there were significant racial disparities in use of MOUD. Regardless, MOUD reduces morbidity associated with OUD and should be offered. Future studies should evaluate if differences in outcomes exist between patients taking methadone versus buprenorphine.